Immunoglobulin Light Chain Al Amyloidosis clinical trials

Explore recruiting immunoglobulin light chain al amyloidosis clinical trials.

Recruiting immunoglobulin light chain al amyloidosis studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Immunoglobulin Light Chain Al Amyloidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II Trial of Teclistamab in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis

Greece, Italy, France, Germany, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Immunoglobulin Light Chain Al Amyloidosis trials by city

Immunoglobulin Light Chain Al Amyloidosis clinical trials

Recruiting immunoglobulin light chain al amyloidosis studies right now

Teclistamab in Previously Treated AL Amyloidosis

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

Evaluation of Skin Tests in Biotherapy Allergies

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Also recruiting in Europe

A Phase II Trial of Teclistamab in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis

Immunoglobulin Light Chain Al Amyloidosis trials by city

Other conditions